Anthrax antitoxins
The present invention provides compositions useful in preparing and/or serving as antitoxins against Bacillus anthracis , the causative agent of anthrax. The present invention also provides polypeptides and polynucleotides relating to the capillary morphogenisis gene 2 (CMG-2), vectors containing the polynucleotides and polypeptides, and host cells containing related polynucleotide molecules, all used in association with the treatment of, or the research and development of treatments for anthrax. The present invention also relates to methods for identifying molecules that bind CMG-2 and molecules that reduce the toxicity of anthrax toxin. Finally, the present invention provides methods for treating human and non-human animals suffering from anthrax.
1. A method comprising the step of administering to a human or non-human animal infected by or exposed to anthrax a polypeptide that inhibits binding between protective antigen (PA) and human capillary morphogenesis protein-2 (CMG-2) at a level effective to reduce the severity of anthrax infection, wherein said polypeptide comprises residues 44-214 of SEQ ID NO:2 or residues 44-317 of SEQ ID NO:2.
2. The method of claim 1 , wherein said human or non-human animal has an anthrax infection.